Display all Bios
Robert J. Coury is the executive chairman of Mylan's board of directors. Under his leadership, Mylan has been transformed into one of the largest generics and specialty pharmaceutical companies in the world, serving customers in approximately 150 countries and territories.
Coury was elected to Mylan's board of directors in February 2002, having served since 1995 as a strategic advisor to the company. He became the board's vice chairman shortly after his election and was made CEO of the company in September of that same year, a post he held through 2011.
In 2007, Mylan, under Coury's leadership, went from a U.S. focused company, to a global powerhouse. At the time, Mylan was the third largest generics manufacturer in the U.S. By purchasing India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and acquiring the generics business of Europe-based Merck KGaA, Mylan catapulted to the No. 3 position in the industry worldwide. The acquisition of the former "Merck Generics" gave the company unprecedented scale in many critical areas, including an extensive and unique international commercial footprint.
Prior to these game-changing acquisitions, from 2002-2007, Coury helped further position Mylan to prosper long-term in a consolidating industry marked by increasing competition and growing demand worldwide for high quality, affordable pharmaceuticals. During this pre-globalization period, the company more than doubled its manufacturing capacity; expanded investment in research and development; and maintained Mylan's strong industry leadership on key issues, working with policymakers to help create a more level playing field for producers of generic drugs.
Before Mylan, Coury was the principal of Coury Consulting, a boutique business advisory firm he formed in 1989, and The Coury Financial Group, a successful financial and estate planning firm. Coury earned a Bachelor of Science degree in industrial engineering from the University of Pittsburgh.
Heather Bresch is chief executive officer of Mylan, one of the largest generics and specialty pharmaceutical companies in the world. She also serves on the company’s board of directors.
Mylan’s mission is to provide the world’s 7 billion people access to high quality medicine. Over the course of her 20-year career at the company, Bresch has been a champion of initiatives and policy changes aimed at removing barriers that hinder patient access to high quality medicine. She has testified before the U.S. Congress and the U.S. Food and Drug Administration, among other institutions, on issued related to access to medicine.
Some of Bresch’s key policy priorities include working to ensure that everyone living with HIV/AIDS has access to treatment and advocating for treatment soon after diagnosis to ensure better health outcomes, reduce HIV transmissions and create long-term cost savings. As part of this effort, Bresch has worked to call attention to access issues in developing countries for patients in need of antiretroviral (ARV) treatment for HIV/AIDS. Further, she has helped position Mylan as a leader in the development and manufacture of ARVs. Today, approximately one out of three people in the developing world being treated for HIV/AIDS depends on a Mylan ARV product.
In other efforts to drive access to medicine, Bresch is actively advocating for the implementation of a viable abbreviated approval pathway for safe and effective generic versions of biologic drugs to provide patients with access to lower-cost versions of life-saving products. She also is working to increase generic drug utilization around the world, particularly in markets where generic utilization rates remain relatively low.
In addition, Bresch is passionate about increasing awareness of food allergies, which can sometimes lead to a life-threatening allergic reaction, called anaphylaxis. She is active in increasing awareness of the risk, symptoms of anaphylaxis, encouraging preparedness to respond when anaphylaxis occurs, and having immediate access to Epinephrine auto-injectors, as Epinephrine is considered the first-line treatment for anaphylaxis.
Bresch also has been a leading advocate for one quality standard for all drugs sold in the U.S. She was instrumental the development of the Generic Drug User Fee Act and advocated for changes to the Federal Food, Drug and Cosmetic Act of 1938 to arm the U.S. Food and Drug Administration with the resources and authority to regularly inspect U.S. and foreign plants at the same rate, both of which were included in the Food and Drug Administration Safety and Innovation Act (FDASIA).
Earlier in her career, Bresch played a vital role in the passage of the 2003 Medicare Modernization Act, a congressional revision to the Hatch-Waxman Act of 1984, which helped to ensure consumer access to affordable pharmaceuticals.
Throughout her career with Mylan, Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as Mylan’s president, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s chief operating officer and chief integration officer, leading the successful integration of two transformational and game-changing international acquisitions – Matrix Laboratories and Merck KGaA’s generics business. In addition, Bresch has served as head of Mylan’s North America operations.
Bresch has served two consecutive terms as chairman of the Generic Pharmaceutical Association and one term as its vice chairman. Bresch earned her undergraduate degree from West Virginia University.
Rajiv Malik is Mylan's president, and is responsible for the company’s operations. He also serves on Mylan’s board of directors.
Malik’s responsibilities as president include overseeing research and development (R&D), business development, regulatory affairs, manufacturing, quality, supply chain, and medical affairs, as well as the sales and marketing of Mylan’s generics business. He also is responsible for helping lead Mylan’s expansion into emerging and other new commercial markets, such as the company’s commercial launch in India in 2012.
Malik has held important leadership positions at Mylan since January 2007, when the company acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of active pharmaceutical ingredients. At the time of the acquisition, Malik was Matrix's chief executive officer.
Among his earlier contributions at Mylan, Malik played a key role in significantly expanding and diversifying the company’s global product portfolio, pipeline and manufacturing footprint. In partnership with Mylan’s leadership team, he played a significant role in leading the integrations of Mylan and Matrix and Mylan and the generics business of Merck KGaA to leverage the benefits of global scale and vertical and horizontal integration. He also helped establish Mylan as a leader in antiretroviral medicines, particularly in developing markets.
Malik has approximately 30 years of experience in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.
John D. Sheehan is Mylan's chief financial officer (CFO), a position he has held since April 2010. Sheehan leads Mylan's global finance functions, including accounting and control, financial planning and analysis, treasury, investor relations and tax. Sheehan also maintains responsibility for leading Mylan's global IT functions.
Sheehan brings nearly 30 years of professional experience in global corporate finance, accounting, auditing and management. He has held numerous leadership positions, most recently as CFO for Detroit-based Delphi Automotive LLP, a global supplier of automotive electronics and technologies, where he led all aspects of the company's global finance function. Prior to the CFO role, Sheehan held several senior management positions at Delphi, including chief restructuring officer and chief accounting officer and controller.
Before Delphi, Sheehan was a partner at KPMG, a global professional accounting firm, where he worked for 20 years in multiple roles of increasing responsibility and exposure. While at KPMG, Sheehan gained extensive international manufacturing experience and auditing and accounting skills. He also worked in London, Frankfurt, Stuttgart and the U.S. with a variety of KPMG's top-tier clients.
Sheehan earned a bachelor's degree in accounting from St. Bonaventure University, St. Bonaventure, N.Y. He is a member of the American Institute of Certified Public Accountants. Sheehan also served as president of the board of directors for the International School of Stuttgart, Germany, from 1999-2001.
Harry A. (Hal) Korman is Mylan's chief operating officer. Previously, he was president, North America, overseeing the growth and development of Mylan Pharmaceuticals Inc. (MPI), Mylan's generics business in the U.S.; Mylan's Canadian subsidiary and Mylan's unit dose packaging operations.
Earlier, Korman held the positions of president of MPI and senior vice president of Mylan Laboratories Inc. Since joining Mylan through its acquisition of UDL Laboratories, the unit dose operation, in 1996, Korman has held several positions of increasing responsibility, including president of UDL and vice president of Sales and Marketing for MPI. He was a Sales Representative for Berlex Laboratories Inc. for approximately eight years.
Korman earned a bachelor's degree in marketing/distributive education from the University of Wisconsin.
Anthony Mauro is the president of Mylan North America, overseeing all business operations in that region. Throughout his 17 year tenure at Mylan, one of the world’s leading generics and specialty pharmaceutical companies, Mauro has held roles of increasing responsibility, including president of Mylan Pharmaceuticals Inc., the company’s flagship generics division in the U.S. Previously, Mauro served as chief operating officer for Mylan Pharmaceuticals ULC in Canada, vice president of North America Strategic Development and vice president of North America Sales.
In 2013, Mauro was elected to serve a second one-year term as chairman of the board of directors for the Generic Pharmaceutical Association (GPhA), which represents the world’s leading generic pharmaceuticals manufacturers and suppliers. Mauro’s appointment further supports Mylan’s mission to impact the future through passionate global leadership on the important policies shaping the generics industry today. Mauro previously served two consecutive terms as vice chairman of the board for GPhA.
Mauro is a member of the visiting committee at the West Virginia University Graduate School of Business and Economics. Mauro earned a bachelor's degree in business administration, with a specialization in finance, and a master's degree in business administration from West Virginia University.
Enrico Baroncia is president of Mylan’s commercial operations in Europe. Previously, he was responsible for the Mylan’s commercial operations in Italy. He joined the company in 2007.
Earlier in his career, Baroncia held senior sales and marketing positions in Italy at leading global health care companies, including Johnson & Johnson, GE Healthcare and Schering Plough.
Baroncia earned a bachelor's degree in biology from Camerino University (Italy).
1500 Corporate DriveCanonsburg, Pa. 15317Tel: 724.514.1800Contact Us Online
Copyright ©2013 Mylan Inc. All Rights Reserved.